Thesis
OPC1's DOSED trial in chronic SCI tests whether oligodendrocyte progenitor cell therapy can restore function in a historically intractable disease
OPC1 is a hESC-derived oligodendrocyte progenitor cell therapy targeting chronic and subacute spinal cord injury in neurologically complete AIS grade A patients. The thesis resolves on whether interim Phase 1/2a DOSED data demonstrates meaningful neurological recovery in chronic SCI patients. The primary risk is that no approved cellular or biological therapy has ever shown functional recovery in chronic complete SCI, setting a high evidentiary bar against a backdrop of failed prior programs including Asterias's AST-OPC1.
Focus
OPC1 DOSED Phase 1/2a interim data readout (chronic and subacute SCI)
2026
Bull
A positive interim readout would show measurable sensory or motor improvement on AIS conversion or ISNCSCI scoring in neurologically complete (AIS-A) patients, demonstrating that oligodendrocyte progenitor cells can remyelinate and restore function in chronic, fully established SCI. This would be a historic proof-of-concept validating the entire OPC1 platform and could unlock partnership interest, non-dilutive capital, and a clear path to an expanded pivotal study.
Bear
The most likely failure modes are absence of functional improvement in AIS-A patients — the most severe and least plastic injury grade — where decades of established biology suggest chronically injured spinal cords may be too scarred and inhibitory for meaningful regeneration. Secondary risks include safety signals from intraspinal injection in chronic injury, insufficient cell engraftment or survival confirmed by biomarker absence, or patient dropout in this small early cohort that renders the data uninterpretable.
Unlock the full thesis for LCTX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.